Is digoxin appropriate for managing heart failure in a patient with aortic stenosis?

Digoxin Use in Aortic Stenosis with Heart Failure

Digoxin should be used with extreme caution or avoided in patients with aortic stenosis and heart failure, as the FDA explicitly warns that patients with idiopathic hypertrophic subaortic stenosis may have worsening of outflow obstruction due to digoxin's inotropic effects 1.

Critical Safety Concern

The FDA drug label specifically identifies aortic stenosis as a condition requiring special consideration, stating: "Patients with idiopathic hypertrophic subaortic stenosis may have worsening of the outflow obstruction due to the inotropic effects of digoxin" 1. While this warning specifically mentions hypertrophic subaortic stenosis, the underlying mechanism—increased contractility worsening a fixed outflow obstruction—applies to valvular aortic stenosis as well.

Theoretical Harm in Aortic Stenosis

• Increased contractility from digoxin's positive inotropic effect can worsen the pressure gradient across a stenotic aortic valve, potentially exacerbating symptoms and hemodynamic compromise 1.
• The FDA further warns that "patients with certain disorders involving heart failure associated with preserved left ventricular ejection fraction may be particularly susceptible to toxicity," which may include some aortic stenosis patients with preserved EF 1.

When Digoxin Might Be Considered

If digoxin is being contemplated despite aortic stenosis, it should only be in highly specific circumstances:

For Heart Failure with Reduced Ejection Fraction (HFrEF)

• Digoxin may be considered in symptomatic HFrEF patients (LVEF <40%) who remain symptomatic despite guideline-directed medical therapy, but only after careful risk-benefit assessment in the context of aortic stenosis 2.
• The 2022 AHA/ACC/HFSA guidelines give digoxin only a Class 2b recommendation (may be considered) for reducing HF hospitalizations in HFrEF patients unable to tolerate or remaining symptomatic on GDMT 2.
• The ESC guidelines note digoxin improves ventricular function and reduces HF hospitalizations but has no effect on survival (Class IIa, Level B) 2.

For Rate Control in Atrial Fibrillation

• If the patient has concurrent atrial fibrillation with rapid ventricular response, digoxin is recommended for rate control in patients with HF and reduced EF (Class I recommendation) 2.
• For acute rate control in HF patients with AF, intravenous digoxin or amiodarone is recommended (Class I, Level B) 2.
• Beta-blockers remain the preferred long-term rate control agent, either alone or combined with digoxin 2.

Practical Dosing Considerations If Used

If digoxin is deemed necessary despite aortic stenosis:

• Start with low doses: 0.125 mg daily or every other day, particularly in elderly patients, those with renal impairment, or low lean body mass 2.
• Target serum digoxin concentration of 0.5-0.9 ng/mL or 0.6-1.2 ng/mL, as higher levels (≥1.2 ng/mL) are associated with increased mortality 2.
• Monitor serum electrolytes (especially potassium) and renal function serially, as hypokalemia increases risk of digoxin-induced arrhythmias 2.

Alternative Management Strategy

The definitive treatment for severe aortic stenosis with heart failure is aortic valve replacement (transcatheter or surgical), not medical optimization with digoxin 3.

• For patients with severe AS and HF, focus should be on evaluation for valve intervention rather than adding digoxin 3.
• Even moderate AS may contribute to HF symptoms and warrant consideration of intervention in selected cases 4.
• Optimize other guideline-directed medical therapy (ACE inhibitors/ARBs, beta-blockers, aldosterone antagonists, SGLT2 inhibitors) while pursuing valve intervention 2, 3.

Key Caveats

• The landmark DIG trial that established digoxin's role in HF predated modern GDMT and excluded patients with significant valvular disease 5.
• No randomized trial data exist specifically examining digoxin safety or efficacy in patients with aortic stenosis and heart failure.
• The recent DIGIT-HF trial (2025) showed benefit with digitoxin (a related cardiac glycoside) in HFrEF, but again, patients with significant valvular disease were likely excluded 6.